No Data
TD Cowen Maintains Jade Biosciences(JBIO.US) With Buy Rating
Wedbush Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $24
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Initiates Coverage on Jade Biosciences With Outperform Rating
William Blair Initiates Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $14.05
Jade: Differentiated IgAN Profile and Multi-Asset Upside Make $2B Peak Sales for JADE101 Look Conservative
TheDylz OP : In summary, JBIO is actively developing drug candidates in the preclinical and early clinical stages, but does not currently have approved, commercialized drugs on the market.
TheDylz OP : strange how rhe chart on webull for the same time frame looks completely different lol
TheDylz OP TheDylz OP : they generate $0 revenue